Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>GlaxoSmithKline (GSK) has reported its 2024 financial results, highlighting both positive trends and areas of concern for potential investors.</li><li>A detailed overview of GSK's performance and strategic initiatives underlines key aspects that can inform an investment thesis.</li><li>On the positive side, GSK's transformation post-demerger into a biopharma-focused company is evident through robust growth in specialty medicines, which now form a significant portion of the company's portfolio.</li></ul>

GlaxoSmithKline (GSK) has reported its 2024 financial results, highlighting both positive trends and areas of concern for potential investors.A detailed overview of GSK's performance and strategic initiatives underlines key aspects that can inform an investment thesis.On the positive side, GSK's transformation post-demerger into a biopharma-focused company is evident through robust growth in specialty medicines, which now form a significant portion of the company's portfolio.

GSK Plc.: Will its Broader Vaccine Portfolio & International Expansion Strengthen Its Competitive Position Internationally?

<ul><li>GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its strategic direction and immediate financial health.</li><li>For the third quarter, GSK reported a 9% sales growth year-to-date and a 19% profit growth.</li><li>This growth primarily stems from the acceleration in Specialty Medicines which underscores GSK’s strategic shift towards high margin areas.</li></ul>

GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its strategic direction and immediate financial health.For the third quarter, GSK reported a 9% sales growth year-to-date and a 19% profit growth.This growth primarily stems from the acceleration in Specialty Medicines which underscores GSK’s strategic shift towards high margin areas.

GlaxoSmithKline (GSK): Will The Acquisition of Novel Lupus Therapy from Chimagen Be A Game Changer? - Major Drivers

<ul><li>GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion.</li><li>Highlighting the company's effective operational execution and a diverse portfolio, GSK's core operating profit improved by 21% to GBP 2.5 billion, and core earnings per share increased by 17% to 43.4p, all figures adjusted to exclude contributions from COVID solutions.</li><li>This demonstrates GSK's ability to achieve profitable growth driven by both its longstanding and newly launched products.</li></ul>

GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion.Highlighting the company's effective operational execution and a diverse portfolio, GSK's core operating profit improved by 21% to GBP 2.5 billion, and core earnings per share increased by 17% to 43.4p, all figures adjusted to exclude contributions from COVID solutions.This demonstrates GSK's ability to achieve profitable growth driven by both its longstanding and newly launched products.

GlaxoSmithKline plc: Will Its Enhanced Focus on Immunotherapy and Oncology Yield Dividends? - Major Drivers

<ul><li>GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its product portfolio in pharmaceuticals and healthcare.</li><li>The company reported a 13% growth in sales to GBP 7.9 billion and a 21% increase in core operating profit to GBP 2.5 billion.</li><li>Core earnings per share also rose by 17% to 43.4p, excluding COVID solutions.</li></ul>

GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its product portfolio in pharmaceuticals and healthcare.The company reported a 13% growth in sales to GBP 7.9 billion and a 21% increase in core operating profit to GBP 2.5 billion.Core earnings per share also rose by 17% to 43.4p, excluding COVID solutions.

GlaxoSmithKline plc: Enhancing Market Position with AREXVY and Other Major Brands! - Major Drivers

<ul><li>GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product launches.</li><li>Total sales increased by 13% to GBP 7.4 billion, with core operating profit surging by 35% to GBP 2.4 billion, and core earnings per share growing by 37% to 43.1p.</li><li>These figures exclude contributions from COVID solutions, underscoring the company's success in its core operations.</li></ul>

GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product launches.Total sales increased by 13% to GBP 7.4 billion, with core operating profit surging by 35% to GBP 2.4 billion, and core earnings per share growing by 37% to 43.1p.These figures exclude contributions from COVID solutions, underscoring the company's success in its core operations.

GlaxoSmithKline plc (GSK): What Is The Development In Terms Of Pipeline Development & Recent Technological Advancements? - Major Drivers

United States

GSK PLC operates as a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GSK provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GSK (GSK US)

GSK Plc.: Will its Broader Vaccine Portfolio & International Expansion Strengthen Its Competitive Position Internationally?

GlaxoSmithKline (GSK) has reported its 2024 financial results, highlighting both positive trends and areas of concern for potential investors. A...

Baptista Research

GlaxoSmithKline (GSK): Will The Acquisition of Novel Lupus Therapy from Chimagen Be A Game Changer? - Major Drivers

GSK has reported a solid performance for Q3, demonstrating resilience amid market challenges, and importantly, provides insights into its...

Baptista Research

GlaxoSmithKline plc: Will Its Enhanced Focus on Immunotherapy and Oncology Yield Dividends? - Major Drivers

GSK has reported a strong performance for its second quarter of the year, with a 13% increase in sales to GBP 7.9 billion. Highlighting the...

Baptista Research

GlaxoSmithKline plc: Enhancing Market Position with AREXVY and Other Major Brands! - Major Drivers

GSK's recent quarterly report underlines a robust upward trajectory with significant growth figures, showcasing the strength and diversity of its...

Baptista Research

GlaxoSmithKline plc (GSK): What Is The Development In Terms Of Pipeline Development & Recent Technological Advancements? - Major Drivers

GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)